Novo Nordisk’s CagriSema Weight Loss Drug Trial Results Disappoint Investors
Novo Nordisk announced results from the REDEFINE 2 phase 3 trial of CagriSema, a combination of cagrilintide and semaglutide13.
Patients taking CagriSema achieved an average weight loss of 15.7% after 68 weeks, compared to 3.1% for those on placebo34.
The trial included 1,206 people with obesity or overweight and type 2 diabetes3.
Novo Nordisk's stock price fell approximately 9% following the announcement of the trial results25.
The weight loss achieved in this trial was lower than the 22.7% reported in the previous REDEFINE 1 trial14.
Investors were disappointed as the results fell short of expectations for 25%+ weight loss4.
Novo Nordisk plans to file for regulatory approval of CagriSema in the first quarter of 202634.
The company will present more detailed analyses from both REDEFINE trials at a scientific conference in 20253.
CagriSema is being investigated as a treatment for adults with obesity or overweight, as well as for those with type 2 diabetes1.
The trial results suggest CagriSema's efficacy, but raise questions about its competitiveness in the growing weight loss drug market4.
Sources:
1. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915082
2. https://www.marketscreener.com/quote/stock/NOVO-NORDISK-A-S-1412980/news/Health-Care-Down-as-Novo-Nordisk-Plunges-Health-Care-Roundup-49290284/
3. https://www.foxbusiness.com/markets/novo-nordisk-shares-fall-weight-loss-drug-trial
4. https://www.fiercebiotech.com/biotech/novo-nordisk-links-cagrisema-16-weight-loss-sending-stock-down-again
5. https://www.marketbeat.com/instant-alerts/novo-nordisk-as-nysenvo-trading-down-9-should-you-sell-2025-03-10/